Medtronic Raises 2027 Forecasts on Strong Heart Device Demand

Medtronic has revised its fiscal 2027 revenue and profit forecasts upwards, citing a surge in demand for its heart devices. The company now anticipates annual organic revenue growth between 7.25% and 7.75%, an increase from the earlier projection of 6.75% to 7.25%.

Strategic Investments Fuel Growth

In a strategic move, Medtronic announced an $80 million investment in heart-valve repair device maker Pi-Cardia, with an option to acquire the company for $210 million. Additionally, it poured $700 million into Cornerstone Robotics, securing rights to distribute a robotic surgical device in select markets outside the United States. According to CEO Geoff Martha, these investments align with the company's focus on high-growth segments within the medtech industry.

Financial Performance and Market Dynamics

Medtronic's cardiovascular segment reported a 19.5% increase in quarterly sales, reaching $3.93 billion. This growth was largely driven by an 88% rise in its pulsed field ablation portfolio, designed to treat irregular heart rhythms. The company posted an adjusted quarterly per share profit of $1.45 on revenues of $9.76 billion, surpassing estimates of $1.39 per share on $9.55 billion in sales, according to data compiled by LSEG.

CEO Geoff Martha emphasized the breadth of performance across Medtronic's businesses and highlighted the contributions from newer growth platforms as key factors in the company's optimistic outlook. The company raised the lower end of its fiscal 2027 adjusted per share profit forecast to $5.94 from $5.90, maintaining the upper end at $6.

Market Opportunities and Future Prospects

Medtronic's investment in Cornerstone Robotics is particularly strategic, given the low penetration of soft tissue robotic surgery in emerging markets, which currently stands at less than 1%. Martha noted that Cornerstone's Sentire device complements Medtronic's existing Hugo system, enhancing its product offerings in the robotic surgery space.

Despite receiving tariff refunds that nearly offset the duties paid during the quarter, Medtronic's finance chief Thierry Pieton stated that future refunds have not been factored into the company's outlook. This cautious approach underscores Medtronic's focus on sustainable growth through innovation and strategic acquisitions.